İnsan vücudunda kendi hücrelerinden çok daha fazla sayıda bakteri yaşamaktadır. Bakterilerin vücutta oluşturduğu bu bakteri topluluğu mikrobiyota olarak ifade edilmektedir. Genel kullanım alanlarına bağlı olarak probiyotikler, kalitatif veya kantitatif olarak bağırsak mikroflorasını değiştirebilen, bağışıklık sistemini destekleyerek yararlı etkilerini tetikleyen, canlılar tarafından tüketilen canlı mikroorganizmalar şeklinde tanımlanmaktadır. Probiyotiklerin yararlı etkileri olduğu bilinmekle beraber, bu preparatların güvenli kullanımı üzerine yeterince çalışma bulunmamaktadır. Bu durum, kontrolsüz bir şekilde bu kadar yaygın olarak kullanılan probiyotiklerin güvenliliklerinin de sorgulanmasını gerektirmektedir. Bu derlemede, tüm dünyada çok popüler olan ve yeterli miktarda verildiğinde hastaya yarar sağlayan canlı mikroorganizmalar olarak tanımlanan probiyotiklerin kullanımının toksikolojik açıdan güvenirliliği ve risk analizi değerlendirilmiştir.
Anahtar Kelimeler: Mikrobiyota; probiyotik; probiyotik güvenlik ve toksisitesi
The number of bacteria in the human body is much higher than their own cell count. This bacterium formed by bacteria in the body is defined as microbiota. Depending on their general field of use, probiotics are defined as living microorganisms that can either qualitatively or quantitatively alter intestinal microflora, support the immune system and trigger beneficial effects. These bacteria have health effects as well as the drugs used and the additional probiotics taken have an effect on the microbiota. Probiotics are known to have beneficial effects, but there is still insufficient study on the safe use of these preparations. This requires an uncontrolled questioning of the safety of such widely used probiotics. In this review, toxicological safety and risk analysis of probiotics identified as living microorganisms, which are very popular all over the world and given sufficient amounts, are evaluated.
Keywords: Microbiota; probiotic; probiotic safety and toxicity
- Adak A, Khan MR. An insight into gut microbiota and its functionalities. Cell Mol Life Sci. 2019;76(3):473-93. [Crossref] [PubMed]
- Anand S, Mande SS. Diet, microbiota and gut-lung connection. Front Microbiol. 2018;9:2147. [Crossref] [PubMed] [PMC]
- Fijan S. Microorganisms with claimed probiotic properties: an overview of recent literature. Int J Environ Res Public Health. 2014;11(5):4745-67. [Crossref] [PubMed] [PMC]
- Anukam KC. Probiotic toxicity, any evidence? J Pharmacol Toxicol. 2007;2(7):590-8. [Crossref]
- Fuller R. Probiotics in man and animals. J Appl Bacteriol. 1989;66(5):365-78. [Crossref]
- Fuller R. Reasons for the apparent variation in the probiotic response. Biologia. 2006;61(6):751-4. [Crossref]
- Salminen S, von Wright A, Morelli L, Marteau P, Brassart D, de Vos WM, et al. Demonstration of safety of probiotics--a review. Int J Food Microbiol. 1998;44(1-2):93-106. [Crossref]
- Riquelme AJ, Calvo MA, Guzmán AM, Depix MS, García P, Pérez C, et al. Saccharomyces cerevisiae fungemia after Saccharomyces boulardii treatment in immunocompromised patients. J Clin Gastroenterol. 2003;36(1):41-3. [Crossref] [PubMed]
- Sotoudegan F, Daniali M, Hassani S, Nikfar S, Abdollahi M. Reappraisal of probiotics' safety in human. Food Chem Toxicol. 2019;129:22-29. [Crossref] [PubMed]
- Cummings JH, Macfarlane GT. The control and consequences of bacterial fermentation in the human colon. J Appl Bacteriol. 1991;70(6):443-59. [Crossref] [PubMed]
- Rolfe RD. The role of probiotic cultures in the control of gastrointestinal health. J Nutr. 2000;130(2S Suppl):396S-402S. [Crossref] [PubMed]
- Feng P, Ye Z, Kakade A, Virk AK, Li X, Liu P. A review on gut remediation of selected environmental contaminants: possible roles of probiotics and gut microbiota. Nutrients. 2018;11(1). pii: E22. [Crossref] [PubMed] [PMC]
- Kau AL, Ahern PP, Griffin NW, Goodman AL, Gordon JI. Human nutrition, the gut microbiome and the immune system. Nature. 2011;474(7351):327-36. [Crossref] [PubMed] [PMC]
- Quigley EMM. Prebiotics and probiotics in digestive health. Clin Gastroenterol Hepatol. 2019;17(2):333-44. [Crossref] [PubMed]
- Suez J, Zmora N, Segal E, Elinav E. The pros, cons, and many unknowns of probiotics. Nat Med. 2019;25(5):716-29. [Crossref] [PubMed]
- Lee ES, Song EJ, Nam YD, Lee SY. Probiotics in human health and disease: from nutribiotics to pharmabiotics. J Microbiol. 2018;56(11):773-82. [Crossref] [PubMed]
- Sanders ME. Probiotics: definition, sources, selection, and uses. Clin Infect Dis. 2008;46 Suppl 2:S58-61. [Crossref] [PubMed]
- Costa-Ribeiro H, Ribeiro TC, Mattos AP, Valois SS, Neri DA, Almeida P, et al. Limitations of probiotic therapy in acute, severe dehydrating diarrhea. J Pediatr Gastroenterol Nutr. 2003;36(1):112-5. [Crossref] [PubMed]
- Borriello SP, Hammes WP, Holzapfel W, Marteau P, Schrezenmeir J, Vaara M, et al. Safety of probiotics that contain lactobacilli or bifidobacteria. Clin Infect Dis. 2003;36(6):775-80. [Crossref] [PubMed]
- Chen J, Cai W, Feng Y. Development of intestinal bifidobacteria and lactobacilli in breast-fed neonates. Clin Nutr. 2007;26(5):559-66. [Crossref] [PubMed]
- Ruiz L, Margolles A, Sánchez B. Bile resistance mechanisms in Lactobacillus and Bifidobacterium. Front Microbiol. 2013;4:396. [Crossref] [PubMed] [PMC]
- Franz CM, Huch M, Abriouel H, Holzapfel W, Gálvez A. Enterococci as probiotics and their implications in food safety. Int J Food Microbiol. 2011;151(2):125-40. [Crossref] [PubMed]
- Burton JP, Chilcott CN, Tagg JR. The rationale and potential for the reduction of oral malodour using Streptococcus salivarius probiotics. Oral Dis. 2005;11 Suppl 1:29-31. [Crossref] [PubMed]
- Wilkins T, Sequoia J. Probiotics for gastrointestinal conditions: a summary of the evidence. Am Fam Physician. 2017;96(3):170-8.
- Guarino A, Lo Vecchio A, Canani RB. İshalin önlenmesi ve tedavisinde probiyotikler. Curr Opin Gastroenterol. 2009;2(2):18-23. [Crossref] [PubMed]
- Tang C, Lu Z. Health promoting activities of probiotics. J Food Biochem. 2019;43(8): e12944. [Crossref]
- Barbara G, De Giorgio R, Stanghellini V, Cremon C, Salvioli B, Corinaldesi R. New pathophysiological mechanisms in irritable bowel syndrome. Aliment Pharm Ther. 2004;20(2):1-9. [Crossref] [PubMed]
- Cho JR, Jun Yoon B, Oh HK. 939 - Effect of probiotics on bowel function restoration after ileostomy reversal in patients with rectal cancer: a double-blind randomized controlled trial. Gastroenterology. 2019;156(6 Suppl 1):S-1421. [Crossref]
- Hooper LV, Gordon JI. Commensal host-bacterial relationships in the gut. Science. 2001;292(5519):1115-8. [Crossref] [PubMed]
- Kim JY, Kwon JH, Ahn SH, Lee SI, Han YS, Choi YO, et al. Effect of probiotic mix (Bifidobacterium bifidum, Bifidobacterium lactis, Lactobacillus acidophilus) in the primary prevention of eczema: a double‐blind, randomized, placebo‐controlled trial. Pediatr Allergy Immunol. 2010;21(2 Pt 2):e386-93. [Crossref] [PubMed]
- Serban DE. Gastrointestinal cancers: influence of gut microbiota, probiotics and prebiotics. Cancer Lett. 2014;345(2):258-70. [Crossref] [PubMed]
- De Almeida CV, de Camargo MR, Russo E, Amedei A. Role of diet and gut microbiota on colorectal cancer immunomodulation. World J Gastroenterol. 2019;25(2):151-62. [Crossref] [PubMed] [PMC]
- Ambalam P, Raman M, Purama RK, Doble M. Probiotics, prebiotics and colorectal cancer prevention. Best Pract Res Clin Gastroenterol. 2016;30(1):119-31. [Crossref] [PubMed]
- Ooi LG, Liong MT. Cholesterol-lowering effects of probiotics and prebiotics: a review of in vivo and in vitro findings. Int J Mol Sci. 2010;11(6):2499-522. [Crossref] [PubMed] [PMC]
- Saarela M, Mogensen G, Fondén R, Mättö J, Mattila-Sandholm T. Probiotic bacteria: safety, functional and technological properties. J Biotechnol. 2000;84(3):197-215. [Crossref]
- Doron S, Snydman DR. Risk and safety of probiotics. Clin Infect Dis. 2015;60 Suppl 2:S129-34. [Crossref] [PubMed] [PMC]
- Hempel S, Newberry SJ, Maher AR, Wang Z, Miles JN, Shanman R, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA. 2012;307(18):1959-69. [Crossref] [PubMed]
- Touchefeu Y. SP-0334 The microbiome and treatment side-effects. Radiother Oncol. 2019;133(Suppl 1):171. [Crossref]
- Zhou J, Shu Q, Rutherfurd K, Prasad J, Gopal PK, Gill HS. Acute oral toxicity and bacterial translocation studies on potentially probiotic strains of lactic acid bacteria. Food Chem Toxicol. 2000;38(2-3):153-61. [Crossref]
- Sanders ME, Akkermans LM, Haller D, Hammerman C, Heimbach J, Hörmannsperger G, et al. Safety assessment of probiotics for human use. Gut Microbes. 2010;1(3):164-85. [Crossref] [PubMed] [PMC]
.: Process List